Texcell opened its newest testing facility in North America, representing a significant milestone in Texcell's commitment to advancing the viral safety of biotherapeutics and medical devices. Designed to support simultaneous viral clearance and biosafety studies, this 27,000 square-foot facility is built with a modular design that enhances the flexibility required in today's contract testing environment. Texcell – North America's dedicated teams are ready to support biosafety studies for monoclonal antibodies, gene therapies, and medical devices coming to the market.
Today marks a momentous occasion for Texcell as they expand their Frederick site. Mayor O'Connor followed with a speech that lauded the growth of the local biotech community that an expanded Texcell will be even better equipped to support. As such, Texcell – North America was recently nominated as one of Maryland's life science companies of the year, a nomination that follows years of steady development supporting the local community. The company's expansion in Frederick signifies an exciting time for the regional biotech hub as Texcell bridges the local community and the global biopharmaceutical industry. As Texcell continues to expand their footprint in Europe and Asia, Texcell-North America remains excited about their future growth prospects locally in Maryland – echoed by the local saying "there's no place like Frederick County!"
